Application of combination of miltinib amine butantriol and PD-L1 antibody in preparation of medicine for treating melanoma
The invention relates to the field of biological medicine, in particular to application of combination of miltinib amine butantriol and a PD-L1 antibody in preparation of a medicine for treating melanoma. The application shows that the miltinib amine butantriol can reduce pyroptosis, enhance the antigen presentation function of macrophages and dendritic cells, weaken the immunosuppression function of bone marrow-derived suppressive cells, enhance the function of effector CD8 + T cells and improve the anti-tumor immune response, thereby improving the survival of mice with melanoma..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 08. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
YANG SHUO [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-12-08, Last update posted on www.tib.eu: 2024-03-04, Last updated: 2024-03-08 |
|---|
| Patentnummer: |
CN117180289 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA019316097 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA019316097 | ||
| 003 | DE-627 | ||
| 005 | 20240308100838.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240308s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA019316097 | ||
| 035 | |a (EPA)CN117180289 | ||
| 035 | |a (EPA)88985306 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a YANG SHUO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of combination of miltinib amine butantriol and PD-L1 antibody in preparation of medicine for treating melanoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-12-08, Last update posted on www.tib.eu: 2024-03-04, Last updated: 2024-03-08 | ||
| 520 | |a The invention relates to the field of biological medicine, in particular to application of combination of miltinib amine butantriol and a PD-L1 antibody in preparation of a medicine for treating melanoma. The application shows that the miltinib amine butantriol can reduce pyroptosis, enhance the antigen presentation function of macrophages and dendritic cells, weaken the immunosuppression function of bone marrow-derived suppressive cells, enhance the function of effector CD8 + T cells and improve the anti-tumor immune response, thereby improving the survival of mice with melanoma. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a WANG BINGWEI |4 aut | |
| 700 | 0 | |a XU HONGYANG |4 aut | |
| 700 | 0 | |a LI HONGHUI |4 aut | |
| 700 | 0 | |a HU YINGCHAO |4 aut | |
| 700 | 0 | |a WEN SHUANG |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 08. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:08 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/88985306/publication/CN117180289A1?q=CN117180289 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 08 |c 12 | ||